A group of cancer patients, their families, and insurers have secured a $55 million class action settlement ending allegations that the maker of Thalomid and Revlimid conspired to keep cheaper, generic versions of the cancer drugs from entering the market.
Class Members include individuals in California, the District of Columbia, Florida, Kansas, Maine, Massachusetts, Michigan, Nebraska, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, and Tennessee, who paid for the cancer treatment drugs Thalomid or Revlimid before Aug. 1, 2019.
Those who paid for the medication on behalf of another are also eligible.
Additionally, Class Members include insurance companies and other health and welfare companies who paid for or reimbursed individuals for the cancer treatment drugs in those states.
The Thalomid Revlimid antitrust class action alleged that Celgene Corporation withheld generic versions of cancer treatment drugs from the market in order to generate more profit.
The plaintiffs accused the company of forcing cancer patients and their loved ones to pay more for life-saving treatment, even though a generic version of the medication was available.
According to the International Myeloma Foundation, Thalomid is an immunomodulatory drug. This means that the drug affects the immune system and, in conjunction with other medications, is considered an effective treatment for multiple myloma — the first in decades when it was introduced in 2006, according to the Foundation.
Thalomid is thought to be a good alternative to Revlimid, an immune modulator, in patients with low blood cell counts.
Celgene produces both drugs and was hit with a number of lawsuits alleging antitrust behavior by both individual consumers and insurance companies. These Thalomid Revlimid antitrust class action lawsuits were consolidated into multidistrict litigation.
Celgene denies any wrongdoing, but has agreed to pay $55 million to end the Thalomid, Revlimid antitrust class action lawsuit.
Under the terms of the settlement, both individuals and third party payors can make claims. Class Members can claim a part of the settlement amount proportionate to their purchases of either Thalomid or Revlimid.
Both individuals and third party payors must submit a Claim Form either online or via mail. Documentation is not required, but the settlement administrator may ask for proof at a later date.
The deadline for Class Members to object to or opt out of the Thalomid Revlimid antitrust class action settlement is Dec. 2, 2019.
Class Members include both individuals, insurance, and other health and welfare companies who “paid for all or some of the purchase price of Thalomid or Revlimid in California, the District of Columbia, Florida, Kansas, Maine, Massachusetts, Michigan, Nebraska, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, or Tennessee any time before August 1, 2019.”
Varies. Claims will vary depending on the purchases of the Class Member.
Proof of Purchase
Not required at this time. However, the settlement administrator may ask for proof later on.
NOTE: If you do not qualify for this settlement do NOT file a claim.
Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.
Claim Form Deadline
In re: Thalomid and Revlimid Antitrust Litigation, Case No. 2:14-cv-06997, in the U.S. District Court for the District of New Jersey
In re Thalomid and Revlimid Antitrust Litigation Settlement Administrator
c/o KCC Class Action Services LLC
PO Box 43143
Melinda R. Coolidge
John E. Schmidtlein
WILLIAMS & CONNOLLY LLP
Top Class Actions is a Proud Member of the American Bar Association
LEGAL INFORMATION IS NOT LEGAL ADVICE
©2008 – 2019 Top Class Actions® LLC
Various Trademarks held by their respective owners
This website is not intended for viewing or usage by European Union citizens.
Please note: Top Class Actions is not a settlement administrator or law firm. Top Class Actions is a legal news source that reports on class action lawsuits, class action settlements, drug injury lawsuits and product liability lawsuits. Top Class Actions does not process claims and we cannot advise you on the status of any class action settlement claim. You must contact the settlement administrator or your attorney for any updates regarding your claim status, claim form or questions about when payments are expected to be mailed out.